Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Int J Hematol
    May 2024
  1. KAITO Y, Imai Y
    Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
    Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778.
    >> Share

    April 2024
  2. KATSUKI K, Tachibana T, Izumi A, Kim K, et al
    Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies.
    Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775.
    >> Share

  3. TIEN FM, Hou HA
    CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.
    Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773.
    >> Share

  4. FUJITA H
    JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
    Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749.
    >> Share

  5. IRIYAMA N, Iwanaga E, Kimura Y, Watanabe N, et al
    Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
    Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758.
    >> Share

  6. TODA Y, Ashizawa M, Murahashi R, Nakashima H, et al
    Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
    Int J Hematol. 2024 Apr 5. doi: 10.1007/s12185-024-03752.
    >> Share

  7. NAKAMURA T, Oya S, Ozawa H, Maehiro Y, et al
    Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.
    Int J Hematol. 2024;119:426-431.
    >> Share

    March 2024
  8. USUKI K, Miyamoto T, Yamauchi T, Ando K, et al
    A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733.
    >> Share

  9. XU J, Zong S, Sheng T, Zheng J, et al
    Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03732.
    >> Share

  10. IOANNIDOU M, Avgeros C, Georgiou E, Papadimitriou-Tsantarliotou A, et al
    Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of children being treated for acute lymphoblastic leukemia.
    Int J Hematol. 2024 Mar 20. doi: 10.1007/s12185-024-03748.
    >> Share

  11. TAKIZAWA J, Suzuki R, Izutsu K, Kiguchi T, et al
    Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.
    Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03741.
    >> Share

  12. KAWAKAMI Y, Imamura M, Imai C
    Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
    Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03756.
    >> Share

  13. MAEDA Y
    JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2024 Mar 14. doi: 10.1007/s12185-024-03730.
    >> Share

  14. SANO H, Fukushima K, Yano M, Osone S, et al
    Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
    Int J Hematol. 2024 Mar 9. doi: 10.1007/s12185-024-03745.
    >> Share

  15. XUE S, Sun HP, Huang XB, Chen X, et al
    Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
    Int J Hematol. 2024 Mar 5. doi: 10.1007/s12185-024-03729.
    >> Share

  16. AN K, He Y, Tang Y, Gu X, et al
    Histiocytic sarcoma following CAR T-cell therapy: a case report.
    Int J Hematol. 2024;119:338-341.
    >> Share

    February 2024
  17. SHIOZAWA Y, Fujita S, Nannya Y, Ogawa S, et al
    First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants.
    Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03724.
    >> Share

  18. CHOED-AMPHAI C, Khorana J, Sathitsamitphong L, Natesirinilkul R, et al
    Predictive factors for L-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03725.
    >> Share

  19. YOKOYAMA Y
    Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.
    Int J Hematol. 2024 Feb 22. doi: 10.1007/s12185-023-03696.
    >> Share

  20. HISADA Y
    Dysregulated hemostasis in acute promyelocytic leukemia.
    Int J Hematol. 2024 Feb 11. doi: 10.1007/s12185-024-03708.
    >> Share

  21. YANAGI M, Mori M, Honda M, Mitani Y, et al
    Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
    Int J Hematol. 2024 Feb 1. doi: 10.1007/s12185-023-03701.
    >> Share

  22. MARUYAMA D, Omi A, Nomura F, Touma T, et al
    Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
    Int J Hematol. 2024;119:146-155.
    >> Share

  23. SCHALK E, Pelz AF
    Auer rods in mature granulocytes in peripheral blood.
    Int J Hematol. 2024;119:105-106.
    >> Share

  24. USUKI K, Ohtake S, Honda S, Matsuda M, et al
    Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
    Int J Hematol. 2024;119:130-145.
    >> Share

    January 2024
  25. UEKI H, Ogawa C, Goto H, Nishi M, et al
    TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.
    Int J Hematol. 2024 Jan 25. doi: 10.1007/s12185-024-03710.
    >> Share

  26. OKAYAMA Y, Harada N, Makuuchi Y, Kuno M, et al
    Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission.
    Int J Hematol. 2024 Jan 22. doi: 10.1007/s12185-023-03707.
    >> Share

  27. KATO K, Takagi S, Takano H, Tsunoda S, et al
    A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.
    Int J Hematol. 2024 Jan 18. doi: 10.1007/s12185-023-03691.
    >> Share

  28. OYAKE M, Hirakuni Y, Hirano N, Suenobu S, et al
    Abnormal bone marrow T1-weighted MRI images in a pediatric patient with acute lymphoblastic leukemia without peripheral blasts.
    Int J Hematol. 2024 Jan 3. doi: 10.1007/s12185-023-03697.
    >> Share

  29. USUKI K, Ohtake S, Honda S, Matsuda M, et al
    Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
    Int J Hematol. 2024;119:24-38.
    >> Share

  30. ITO M, Fukushima N, Fujii T, Numata M, et al
    Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2024;119:80-87.
    >> Share

    December 2023
  31. MAKITA S, Ota S, Mishima Y, Usuki K, et al
    Japanese phase Ib study of the oral PI3K-delta and -gamma inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Int J Hematol. 2023 Dec 27. doi: 10.1007/s12185-023-03689.
    >> Share

  32. ZHAO B, Yin J, Ding L, Luo J, et al
    SPAG6 regulates cell proliferation and apoptosis via TGF-beta/Smad signal pathway in adult B-cell acute lymphoblastic leukemia.
    Int J Hematol. 2023 Dec 26. doi: 10.1007/s12185-023-03684.
    >> Share

  33. NUKUI J, Tachibana T, Miyazaki T, Tanaka M, et al
    Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2023 Dec 12. doi: 10.1007/s12185-023-03688.
    >> Share

  34. TAKEYASU S, Morita K, Saito S, Toho M, et al
    Myeloid sarcoma and pathological fracture: a case report and review of literature.
    Int J Hematol. 2023;118:745-750.
    >> Share

  35. MIKI K, Ogasawara R, Sugimura S, Sugita J, et al
    A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation.
    Int J Hematol. 2023;118:766-771.
    >> Share

    November 2023
  36. SHIOMI I, Nakako S, Nakane T, Ogawa Y, et al
    Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.
    Int J Hematol. 2023 Nov 27. doi: 10.1007/s12185-023-03678.
    >> Share

  37. SAKAI Y, Ikawa Y, Takenaka M, Noguchi K, et al
    Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis.
    Int J Hematol. 2023 Nov 21. doi: 10.1007/s12185-023-03675.
    >> Share

    October 2023
  38. FUKATSU M, Hamazaki Y, Sato Y, Koyama D, et al
    A case of cold agglutinin syndrome associated with chronic lymphocytic leukaemia harbouring mutations in CARD11 and KMT2D.
    Int J Hematol. 2023;118:472-476.
    >> Share

  39. UNO S, Motegi Y, Minehata K, Aoki Y, et al
    Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
    Int J Hematol. 2023;118:432-442.
    >> Share

    September 2023
  40. ZHANG A, Liu L, Zong S, Chang L, et al
    Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 x 10(9)/L.
    Int J Hematol. 2023 Sep 21. doi: 10.1007/s12185-023-03665.
    >> Share

  41. HARA R, Machida S, Hashimoto N, Ogiya D, et al
    Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax.
    Int J Hematol. 2023 Sep 20. doi: 10.1007/s12185-023-03664.
    >> Share

  42. YAMAMOTO M, Akane Y, Hamada R, Kabutoya H, et al
    Rivaroxaban for severe superior sagittal sinus thrombosis in a child with ALL.
    Int J Hematol. 2023;118:309-310.
    >> Share

    August 2023
  43. IZUTSU K, Yamamoto K, Kato K, Ishikawa T, et al
    Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
    Int J Hematol. 2023 Aug 15. doi: 10.1007/s12185-023-03646.
    >> Share

  44. OKAMOTO K, Imamura T, Tanaka S, Urata T, et al
    The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells.
    Int J Hematol. 2023;118:277-287.
    >> Share

  45. NAJIMA Y
    Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.
    Int J Hematol. 2023;118:169-182.
    >> Share

    July 2023
  46. BABA Y, Nakamaki T, Sakai H, Fukuchi K, et al
    Chronic neutrophilic leukemia preceded by myelodysplastic syndromes.
    Int J Hematol. 2023 Jul 13. doi: 10.1007/s12185-023-03636.
    >> Share

    June 2023
  47. YANO M, Ishida H, Hara J, Kawaguchi H, et al
    Outcome of hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia not in remission enrolled in JACLS ALL-02.
    Int J Hematol. 2023 Jun 26. doi: 10.1007/s12185-023-03626.
    >> Share

  48. HAEFLIGER S, Tzankov A
    Mycobacterial spindle cell pseudotumor mimicking Richter transformation in a patient with hairy cell leukemia.
    Int J Hematol. 2023 Jun 23. doi: 10.1007/s12185-023-03628.
    >> Share

  49. FUJITA T, Fukushima H, Nanmoku T, Arakawa Y, et al
    Acute monocytic leukemia with KMT2A::LASP1 developed 9 months after diagnosis of acute megakaryoblastic leukemia in a 2-year-old boy.
    Int J Hematol. 2023 Jun 14. doi: 10.1007/s12185-023-03622.
    >> Share

  50. BARAKAT C, Inagaki Y, Mizuno S, Nishio N, et al
    Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation.
    Int J Hematol. 2023 Jun 13. doi: 10.1007/s12185-023-03621.
    >> Share

  51. ZHAO Y, Jiang S, Tang Y, Zhao L, et al
    Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.
    Int J Hematol. 2023 Jun 3. doi: 10.1007/s12185-023-03623.
    >> Share

  52. SASHIDA G
    Stem cell regulation and dynamics in myeloid malignancies.
    Int J Hematol. 2023;117:789-790.
    >> Share

  53. ABDALLAH MG, Teoh VSI, Dutta B, Yokomizo T, et al
    Childhood hematopoietic stem cells constitute the permissive window for RUNX1-ETO leukemogenesis.
    Int J Hematol. 2023;117:830-838.
    >> Share

  54. YANG FC, Agosto-Pena J
    Epigenetic regulation by ASXL1 in myeloid malignancies.
    Int J Hematol. 2023;117:791-806.
    >> Share

  55. JIN Z, MacPherson K, Liu Z, Vu LP, et al
    RNA modifications in hematological malignancies.
    Int J Hematol. 2023;117:807-820.
    >> Share

  56. TUNGALAG S, Shinriki S, Hirayama M, Nagamachi A, et al
    Ribosome profiling analysis reveals the roles of DDX41 in translational regulation.
    Int J Hematol. 2023;117:876-888.
    >> Share

  57. FUKUTA T, Tanaka T, Hashimoto T, Isahaya K, et al
    Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases.
    Int J Hematol. 2023;117:933-940.
    >> Share

    May 2023
  58. ZHANG X, Cui B, Li Y, Li Z, et al
    Transcriptome sequencing identifies novel EVX fusions involved in transcriptional activation of HOX family genes in pediatric immature T-cell acute lymphoblastic leukemia: two cases reports and a literature review.
    Int J Hematol. 2023 May 27. doi: 10.1007/s12185-023-03619.
    >> Share

  59. AL-SHAIBANI E, Novitzky-Basso I, Mattsson J, Kim DDH, et al
    Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
    Int J Hematol. 2023 May 22. doi: 10.1007/s12185-023-03614.
    >> Share

  60. TOKUHIRA M, Kimura Y, Tabayashi T, Watanabe N, et al
    Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.
    Int J Hematol. 2023 May 2. doi: 10.1007/s12185-023-03606.
    >> Share

  61. MIYAGAWA N, Goto H, Ogawa A, Kikuta A, et al
    Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia.
    Int J Hematol. 2023 May 1. doi: 10.1007/s12185-023-03609.
    >> Share

    April 2023
  62. LANGABEER SE, Jones A, Conneally E, Enright H, et al
    Frequency and driver mutation diversity of concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm.
    Int J Hematol. 2023 Apr 26. doi: 10.1007/s12185-023-03611.
    >> Share

  63. IMAI C, Sato A, Hiwatari M, Shimomura Y, et al
    Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia.
    Int J Hematol. 2023 Apr 10. doi: 10.1007/s12185-023-03600.
    >> Share

  64. NOGUCHI K, Ikawa Y, Takenaka M, Sakai Y, et al
    L-asparaginase as an efficient salvage therapy for refractory acute myeloid leukemia with chromosome 7 abnormalities: a case series.
    Int J Hematol. 2023 Apr 6. doi: 10.1007/s12185-023-03591.
    >> Share

  65. MUNAKATA W, Ando K, Yokoyama M, Fukuhara N, et al
    Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.
    Int J Hematol. 2023;117:553-562.
    >> Share

    March 2023
  66. FUKUSHIMA H, Morita K, Ikemura M, Tanaka M, et al
    Acute pancreatitis as the initial manifestation of acute myeloid leukemia with chromosome 16 rearrangements.
    Int J Hematol. 2023 Mar 25. doi: 10.1007/s12185-023-03580.
    >> Share

  67. NAKAYAMA H, Ogawa C, Sekimizu M, Fujisaki H, et al
    Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Int J Hematol. 2023 Mar 21. doi: 10.1007/s12185-023-03584.
    >> Share

  68. NAKAMURA F, Seo S, Nannya Y, Ayabe R, et al
    Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12).
    Int J Hematol. 2023 Mar 17. doi: 10.1007/s12185-023-03577.
    >> Share

  69. TORATANI K, Watanabe M, Kanda J, Oka T, et al
    Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations.
    Int J Hematol. 2023 Mar 10. doi: 10.1007/s12185-023-03575.
    >> Share

  70. ALEEM A, Alotaibi G, Iqbal Z, AlFaifi A, et al
    Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia.
    Int J Hematol. 2023 Mar 9. doi: 10.1007/s12185-023-03569.
    >> Share

  71. SHIRAI R, Osumi T, Keino D, Nakabayashi K, et al
    Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
    Int J Hematol. 2023 Mar 3. doi: 10.1007/s12185-023-03566.
    >> Share

  72. ZHENG Q, Liao H
    Blasts engulfing erythrocytes: an unusual morphological finding in adult early T-precursor acute lymphoblastic leukemia.
    Int J Hematol. 2023 Mar 2. doi: 10.1007/s12185-023-03574.
    >> Share

  73. KATSUYA H
    Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma.
    Int J Hematol. 2023 Mar 2. doi: 10.1007/s12185-023-03572.
    >> Share

  74. OLIVEIRA AC, Roncero JM, Ferra C, Do Nascimento J, et al
    Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.
    Int J Hematol. 2023;117:388-397.
    >> Share

  75. HAJI S, Shiratsuchi M, Takamatsu A, Tsuda M, et al
    Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2023;117:438-445.
    >> Share

    February 2023
  76. MIYASHITA N, Onozawa M, Yoshida S, Kimura H, et al
    Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
    Int J Hematol. 2023 Feb 28. doi: 10.1007/s12185-023-03567.
    >> Share

  77. WAKAMATSU M, Murata M, Kanda J, Fukushima K, et al
    Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation.
    Int J Hematol. 2023 Feb 22. doi: 10.1007/s12185-023-03563.
    >> Share

  78. NAKASONE H
    Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Int J Hematol. 2023 Feb 20. doi: 10.1007/s12185-023-03556.
    >> Share

  79. ONISHI Y, Furukawa E, Kamata M, Fukatsu M, et al
    Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL.
    Int J Hematol. 2023 Feb 9. doi: 10.1007/s12185-023-03546.
    >> Share

  80. YOSHIDA C, Yamaguchi H, Doki N, Murai K, et al
    Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
    Int J Hematol. 2023 Feb 4. doi: 10.1007/s12185-023-03549.
    >> Share

  81. OBO T, Morita K, Sumida Y, Nakazaki-Watadani K, et al
    Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review.
    Int J Hematol. 2023 Feb 3. doi: 10.1007/s12185-023-03545.
    >> Share

  82. ZHANG M, Xiao F, Li Y, Chen Z, et al
    The miR-106b-25 cluster mediates drug resistance in myeloid leukaemias by inactivating multiple apoptotic genes.
    Int J Hematol. 2023;117:236-250.
    >> Share

  83. IMAIZUMI Y, Iwanaga M, Nosaka K, Ishitsuka K, et al
    Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study.
    Int J Hematol. 2023;117:206-215.
    >> Share

  84. TANIGUCHI S, Utsumi S, Kochi Y, Taya Y, et al
    Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation.
    Int J Hematol. 2023;117:287-292.
    >> Share

    January 2023
  85. YASUNAGA JI
    Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma.
    Int J Hematol. 2023 Jan 27. doi: 10.1007/s12185-023-03547.
    >> Share

  86. LIU H, Bai H, Zhang S, Zhao X, et al
    Dasatinib for chronic myelomonocytic leukemia with ZMIZ1-ABL1 fusion gene: a case report.
    Int J Hematol. 2023 Jan 24. doi: 10.1007/s12185-023-03531.
    >> Share

  87. SHIBA N
    Comprehensive molecular understanding of pediatric acute myeloid leukemia.
    Int J Hematol. 2023 Jan 18. doi: 10.1007/s12185-023-03533.
    >> Share

  88. IMAMURA T
    Guest editorial: recent progress in pediatric leukemia.
    Int J Hematol. 2023 Jan 13. doi: 10.1007/s12185-023-03536.
    >> Share

  89. CAI Y, Zhang J, Yi M, Zhang W, et al
    Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China.
    Int J Hematol. 2023;117:121-127.
    >> Share

    December 2022
  90. ZHANG X, Wu S, Yang J, Zhang G, et al
    Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
    Int J Hematol. 2022 Dec 29. doi: 10.1007/s12185-022-03507.
    >> Share

  91. HIROKI H, Akahane K, Inukai T, Morio T, et al
    Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells.
    Int J Hematol. 2022 Dec 28. doi: 10.1007/s12185-022-03520.
    >> Share

  92. SHIMA H, Shimada H
    Recent progress in the management of pediatric chronic myeloid leukemia.
    Int J Hematol. 2022 Dec 27. doi: 10.1007/s12185-022-03526.
    >> Share

  93. YOSHIDA S, Onozawa M, Miyashita N, Kimura H, et al
    Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
    Int J Hematol. 2022 Dec 26. doi: 10.1007/s12185-022-03522.
    >> Share

  94. LI H, Niu T, Huang J, Xie L, et al
    The characteristics and long-term outcomes of acute promyelocytic leukemia patients with early intracranial hemorrhage.
    Int J Hematol. 2022 Dec 15. doi: 10.1007/s12185-022-03515.
    >> Share

  95. IRIYAMA N
    Chronic myeloid leukemia: the cutting-edge evidence and things we should know.
    Int J Hematol. 2022 Dec 8. doi: 10.1007/s12185-022-03511.
    >> Share

  96. OCHI Y
    Genetic landscape of chronic myeloid leukemia.
    Int J Hematol. 2022 Dec 7. doi: 10.1007/s12185-022-03510.
    >> Share

  97. GAO L, Lu J, Li J, Hu Y, et al
    Lineage switch in a pediatric patient with KMT2A-MLLT3 from acute megakaryoblastic leukemia to T cell acute lymphoblastic leukemia at the fourth relapse after allo-HSCT: with literature review.
    Int J Hematol. 2022 Dec 6. doi: 10.1007/s12185-022-03504.
    >> Share

  98. IWAI T, Nishida M, Sugita J, Yasumoto A, et al
    Ultrasonographic monitoring of sinusoidal obstruction syndrome in patients treated with inotuzumab ozogamicin.
    Int J Hematol. 2022;116:973-975.
    >> Share

  99. KATO M
    Recent progress in pediatric lymphoblastic leukemia.
    Int J Hematol. 2022 Dec 1. doi: 10.1007/s12185-022-03501.
    >> Share

    November 2022
  100. TOMIZAWA D
    Evolution and optimization of therapies for acute lymphoblastic leukemia in infants.
    Int J Hematol. 2022 Nov 28. doi: 10.1007/s12185-022-03502.
    >> Share

  101. KARADAS N, Goktepe SSO, Bas I, Ece D, et al
    Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment.
    Int J Hematol. 2022 Nov 19. doi: 10.1007/s12185-022-03497.
    >> Share

  102. NAKAMURA Y, Itoh Y, Wakimoto N
    Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
    Int J Hematol. 2022 Nov 14. pii: 10.1007/s12185-022-03492.
    >> Share

  103. YANADA M, Yamasaki S, Konuma T, Mizuno S, et al
    Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
    Int J Hematol. 2022 Nov 6. pii: 10.1007/s12185-022-03486.
    >> Share

  104. WAN L, Ding S, Xu M, Lv K, et al
    Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.
    Int J Hematol. 2022;116:731-743.
    >> Share

  105. LI W, Xu Y, Feng Y, Zhou H, et al
    The clinical application of SNP-based next-generation sequencing (SNP-NGS) for evaluation of chimerism and microchimerism after HLA-mismatched stem cell microtransplantation.
    Int J Hematol. 2022;116:723-730.
    >> Share

  106. LEE FW, Lee CY, Hung GY, Tseng MH, et al
    Recurrent microangiopathic hemolysis after recovery from complement-mediated hemolytic uremia syndrome during chemotherapy for a CFH-mutated patient with T-lymphoblastic lymphoma.
    Int J Hematol. 2022;116:812-818.
    >> Share

  107. KUSUDA M, Nakasone H, Nakamura Y, Kawamura M, et al
    Very early death within 30 days after diagnosis in patients with acute myeloid leukemia.
    Int J Hematol. 2022 Nov 1. pii: 10.1007/s12185-022-03482.
    >> Share

    October 2022
  108. VINOTHKUMAR K, Chanda S, Singh VK, Biswas S, et al
    EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells.
    Int J Hematol. 2022 Oct 25. pii: 10.1007/s12185-022-03465.
    >> Share

  109. ITO J, Yamagata K, Shinohara H, Shima Y, et al
    Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1.
    Int J Hematol. 2022 Oct 24. pii: 10.1007/s12185-022-03469.
    >> Share

  110. YUNIS LK, Linares-Ballesteros A, Barros G, Garcia J, et al
    Genomic alterations in a cohort of pediatric acute myeloid leukemia patients at two cancer centers in Colombia.
    Int J Hematol. 2022 Oct 24. pii: 10.1007/s12185-022-03475.
    >> Share

  111. SEKIGUCHI N, Kasahara S, Miyamoto T, Kiguchi T, et al
    Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia.
    Int J Hematol. 2022 Oct 19. pii: 10.1007/s12185-022-03464.
    >> Share

  112. LEIVA O, Ren S, Neuberg D, Bhatt A, et al
    Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease.
    Int J Hematol. 2022 Oct 2. pii: 10.1007/s12185-022-03454.
    >> Share

  113. HOCHMAN MJ, Smith BD, Karantanos T, Braunstein EM, et al
    Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.
    Int J Hematol. 2022 Oct 1. pii: 10.1007/s12185-022-03463.
    >> Share

    September 2022
  114. UMEZAWA Y, Sasaki K
    Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Int J Hematol. 2022 Sep 10. pii: 10.1007/s12185-022-03431.
    >> Share

  115. SUN H, Yan Z, Zhang S
    Three atypical BCR/ABL transcripts detected simultaneously in a Philadelphia-positive acute lymphoblastic leukemia patient showing resistance to tyrosine kinase inhibitors.
    Int J Hematol. 2022 Sep 10. pii: 10.1007/s12185-022-03451.
    >> Share

  116. HIROSAWA M, Goto M, Oku M, Akao K, et al
    Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study.
    Int J Hematol. 2022 Sep 9. pii: 10.1007/s12185-022-03447.
    >> Share

  117. NARLI OZDEMIR Z, Kilicaslan NA, Yilmaz M, Eskazan AE, et al
    Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.
    Int J Hematol. 2022 Sep 5. pii: 10.1007/s12185-022-03446.
    >> Share

  118. MAGNOLI F, Casiccia L, Ripamonti F, Uccella S, et al
    Simultaneous diagnosis of plasma cell myeloma and chronic lymphocytic leukemia on bone marrow trephine biopsy.
    Int J Hematol. 2022 Sep 2. pii: 10.1007/s12185-022-03443.
    >> Share

  119. BIAVASCO F, Zeiser R
    FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2022;116:341-350.
    >> Share

    August 2022
  120. HAN L, Li Y, Wu J, Peng J, et al
    Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.
    Int J Hematol. 2022 Aug 28. pii: 10.1007/s12185-022-03441.
    >> Share

  121. HOSHINO T, Hatsumi N, Iino H, Takada S, et al
    Therapy-related myeloid neoplasms of recipient origin after allogeneic hematopoietic stem cell transplantation for acute leukemia.
    Int J Hematol. 2022 Aug 28. pii: 10.1007/s12185-022-03442.
    >> Share

  122. SUZUMIYA J, Takizawa J
    Correction to: Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Int J Hematol. 2022 Aug 27. pii: 10.1007/s12185-022-03439.
    >> Share

  123. ONO T, Hino M, Matsumura I, Fujisawa S, et al
    Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
    Int J Hematol. 2022 Aug 13. pii: 10.1007/s12185-022-03435.
    >> Share

  124. AYDIN S, Passera R, Scaldaferri M, Dellacasa CM, et al
    Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
    Int J Hematol. 2022 Aug 9. pii: 10.1007/s12185-022-03427.
    >> Share

  125. TSUDA M, Hirata A, Tokunaga S, Masuda T, et al
    Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia.
    Int J Hematol. 2022 Aug 6. pii: 10.1007/s12185-022-03433.
    >> Share

  126. LAGANA A, Scalzulli E, Carmosino I, Martelli M, et al
    Asciminib as a third line option in chronic myeloid leukemia.
    Int J Hematol. 2022 Aug 5. pii: 10.1007/s12185-022-03432.
    >> Share

    July 2022
  127. HIRADE K, Kusumoto S, Abe A, Noritake H, et al
    A novel RARA-SNX15 fusion in PML-RARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1).
    Int J Hematol. 2022 Jul 19. pii: 10.1007/s12185-022-03421.
    >> Share

  128. HAGINO T, Sato T, Saga R, Hidai H, et al
    Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.
    Int J Hematol. 2022 Jul 19. pii: 10.1007/s12185-022-03422.
    >> Share

  129. CHEN X, Liu L, Zhang A, Yi M, et al
    Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia.
    Int J Hematol. 2022 Jul 18. pii: 10.1007/s12185-022-03402.
    >> Share

  130. KREIDIEH F, Abou Dalle I, Moukalled N, El-Cheikh J, et al
    Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
    Int J Hematol. 2022 Jul 16. pii: 10.1007/s12185-022-03416.
    >> Share

  131. MIYAJIMA T, Hasegawa Y, Hashimoto D, Teshima T, et al
    Unilateral recurrent laryngeal nerve palsy detected by PET/CT in a patient with mediastinal T-cell lymphoblastic lymphoma.
    Int J Hematol. 2022;116:3-4.
    >> Share

  132. YOSHIDA C, Kondo T, Ito T, Kizaki M, et al
    Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
    Int J Hematol. 2022;116:89-101.
    >> Share

  133. HE J, Liu J, Shen H, Wang Z, et al
    Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
    Int J Hematol. 2022;116:71-80.
    >> Share

    June 2022
  134. CAO XY, Li JJ, Lu PH, Liu KY, et al
    Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2022 Jun 23. pii: 10.1007/s12185-022-03398.
    >> Share

  135. MATSUOKA A, Tanibuchi M, Yamazaki I, Taoka T, et al
    Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
    Int J Hematol. 2022;115:852-859.
    >> Share

  136. KAWAKAMI F, Kawakami T, Yamane T, Maruyama M, et al
    T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia.
    Int J Hematol. 2022;115:816-825.
    >> Share

  137. ONISHI Y, Onodera K, Fukuhara N, Kato H, et al
    Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.
    Int J Hematol. 2022;115:873-881.
    >> Share

  138. WATANABE N, Takaku T, Tsukune Y, Yasuda H, et al
    Bosutinib-induced lung injury: a report of two cases and literature review.
    Int J Hematol. 2022;115:902-905.
    >> Share

    May 2022
  139. NAKAYAMA H, Ogawa C, Sekimizu M, Fujisaki H, et al
    A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Int J Hematol. 2022 May 30. pii: 10.1007/s12185-022-03388.
    >> Share

  140. CAPRIA S, Trisolini SM, Diverio D, Minotti C, et al
    Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.
    Int J Hematol. 2022 May 13. pii: 10.1007/s12185-022-03370.
    >> Share

  141. MIZUTA S, Ugai T, Kato H, Doki N, et al
    Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Int J Hematol. 2022 May 10. pii: 10.1007/s12185-022-03368.
    >> Share

  142. TACHIBANA T, Tanaka M, Hagihara M, Fujimaki K, et al
    Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation.
    Int J Hematol. 2022 May 9. pii: 10.1007/s12185-022-03377.
    >> Share

  143. ARAI Y, Chi S, Minami Y, Yanada M, et al
    FLT3-targeted treatment for acute myeloid leukemia.
    Int J Hematol. 2022 May 9. pii: 10.1007/s12185-022-03374.
    >> Share

  144. NGUYEN TTT, Tamai M, Harama D, Kagami K, et al
    Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
    Int J Hematol. 2022 May 6. pii: 10.1007/s12185-022-03369.
    >> Share

  145. FUKUYAMA T, Kitamura T, Kozu T
    UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8.
    Int J Hematol. 2022;115:686-693.
    >> Share

  146. LU N, Lin J, Wang LL, Li YY, et al
    A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
    Int J Hematol. 2022;115:713-727.
    >> Share

    April 2022
  147. SOBIERALSKI P, Bieniaszewska M, Leszczynska A, Zuk M, et al
    Secondary chronic myeloid leukemia in a patient with CALR and ASXL1-mutated primary myelofibrosis.
    Int J Hematol. 2022 Apr 16. pii: 10.1007/s12185-022-03331.
    >> Share

  148. HAYAKAWA J, Nakasone H, Minakata D, Fujiwara SI, et al
    Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2022 Apr 16. pii: 10.1007/s12185-022-03343.
    >> Share

  149. MARUMO A, Wakita S, Morita K, Oh I, et al
    NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
    Int J Hematol. 2022 Apr 4. pii: 10.1007/s12185-022-03328.
    >> Share

    March 2022
  150. KODAMA Y, Sato A, Kato K, Sakaguchi H, et al
    Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group.
    Int J Hematol. 2022 Mar 29. pii: 10.1007/s12185-022-03329.
    >> Share

  151. TASHIRO Y, Kanda J, Iemura T, Kondo T, et al
    Feasibility of ovarian stimulation for fertility preservation during and after blinatumomab treatment for Ph-negative B-cell acute lymphoblastic leukemia.
    Int J Hematol. 2022 Mar 14. pii: 10.1007/s12185-022-03323.
    >> Share

  152. TAKAHASHI Y, Ishida H, Imamura T, Tamefusa K, et al
    JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia.
    Int J Hematol. 2022 Mar 8. pii: 10.1007/s12185-022-03315.
    >> Share

  153. TAKAHASHI N, Cortes JE, Sakaida E, Ishizawa K, et al
    Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
    Int J Hematol. 2022 Mar 2. pii: 10.1007/s12185-022-03314.
    >> Share

  154. ADACHI Y, Sakai T, Terakura S, Shiina T, et al
    Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells.
    Int J Hematol. 2022;115:371-381.
    >> Share

    February 2022
  155. KOJIMA H, Nakayama H, Kosugi N
    Bilateral adrenal hemorrhage: a rare presentation of acute myeloid leukemia.
    Int J Hematol. 2022 Feb 25. pii: 10.1007/s12185-022-03316.
    >> Share

  156. HWANG WL, Chen TC, Lin HY, Chang MC, et al
    NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.
    Int J Hematol. 2022 Feb 25. pii: 10.1007/s12185-022-03311.
    >> Share

  157. IIDA H, Imada K, Ueda Y, Kubo K, et al
    A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.
    Int J Hematol. 2022 Feb 24. pii: 10.1007/s12185-022-03307.
    >> Share

  158. CHENG S, Xiao P, Wang J, Li Z, et al
    Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases.
    Int J Hematol. 2022 Feb 18. pii: 10.1007/s12185-022-03309.
    >> Share

  159. SATO S, Tamai Y
    Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy.
    Int J Hematol. 2022 Feb 8. pii: 10.1007/s12185-022-03296.
    >> Share

  160. MORI A, Onozawa M, Hidaka D, Yokoyama S, et al
    Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
    Int J Hematol. 2022;115:188-197.
    >> Share

  161. SAWADA A, Shimizu M, Koyama-Sato M, Higuchi K, et al
    Radiation-sparing reduced-intensity unrelated umbilical cord blood transplantation for rare hematological disorders in children.
    Int J Hematol. 2022;115:269-277.
    >> Share

  162. WEI X, Zhuang J, Li N, Zheng B, et al
    NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.
    Int J Hematol. 2022;115:278-286.
    >> Share

    January 2022
  163. HIGUCHI K, Sawada A, Kondo O, Okada Y, et al
    HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis.
    Int J Hematol. 2022 Jan 14. pii: 10.1007/s12185-021-03270.
    >> Share

  164. AKAHOSHI Y, Nakasone H, Kusuda M, Kameda K, et al
    Emergence of clone with PHF6 nonsense mutation in chronic myelomonocytic leukemia at relapse after allogeneic HCT.
    Int J Hematol. 2022 Jan 6. pii: 10.1007/s12185-021-03284.
    >> Share

  165. BABA M, Imamura M, Imai C
    Newly diagnosed ETV6-RUNX1-positive B-acute lymphoblastic leukemia localized to the left pelvic bone marrow.
    Int J Hematol. 2022 Jan 4. pii: 10.1007/s12185-021-03269.
    >> Share

  166. GOMEZ-CENTURION I, Oarbeascoa G, Garcia MC, Lopez Fresnena MC, et al
    Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility.
    Int J Hematol. 2022;115:61-68.
    >> Share

    December 2021
  167. OHWADA C, Yamazaki S, Shono K, Kayamori K, et al
    Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.
    Int J Hematol. 2021;114:664-673.
    >> Share

    November 2021
  168. KOBAYASHI S, Sano H, Mochizuki K, Ohara Y, et al
    Effects of second transplantation with T-cell-replete haploidentical graft using low-dose anti-thymocyte globulin on long-term overall survival in pediatric patients with relapse of leukemia after first allogeneic transplantation.
    Int J Hematol. 2021 Nov 25. pii: 10.1007/s12185-021-03266.
    >> Share

  169. NAKAMAE M, Nakamae H, Hashimoto M, Koh H, et al
    Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
    Int J Hematol. 2021 Nov 17. pii: 10.1007/s12185-021-03259.
    >> Share

  170. WANG X, Diamond DJ, Forman SJ, Nakamura R, et al
    Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.
    Int J Hematol. 2021;114:544-553.
    >> Share

    October 2021
  171. HONDA Y, Muramatsu H, Nanjo Y, Hirabayashi S, et al
    A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
    Int J Hematol. 2021 Oct 29. pii: 10.1007/s12185-021-03248.
    >> Share

  172. INOUE Y, Nishimura N, Murai M, Matsumoto M, et al
    Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2021 Oct 27. pii: 10.1007/s12185-021-03250.
    >> Share

  173. SHIBATA S, Inano S, Watanabe M, Fujiwara K, et al
    Identification of an asymptomatic Shwachman-Bodian-Diamond syndrome mutation in a patient with acute myeloid leukemia.
    Int J Hematol. 2021 Oct 26. pii: 10.1007/s12185-021-03251.
    >> Share

  174. IKAWA Y, Takenaka M, Sakai Y, Noguchi K, et al
    Utility of 18F-FDG-PET for detecting acute lymphoblastic leukemia: a case series of pediatric acute lymphoblastic leukemia without hematological symptoms.
    Int J Hematol. 2021 Oct 13. pii: 10.1007/s12185-021-03232.
    >> Share

  175. NUKUI J, Tanaka M, Nakajima H
    A case of multiple brain abscesses due to Bacillus cereus during induction therapy for acute myeloid leukemia.
    Int J Hematol. 2021 Oct 7. pii: 10.1007/s12185-021-03226.
    >> Share

  176. LEE SH, Yoon JH, Min GJ, Park SS, et al
    Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Int J Hematol. 2021 Oct 6. pii: 10.1007/s12185-021-03231.
    >> Share

  177. KAWANO N, Kimura S, Miura M, Tochigi T, et al
    Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
    Int J Hematol. 2021;114:509-516.
    >> Share

    September 2021
  178. DEMBITZ V, Lalic H, Tomic B, Smoljo T, et al
    All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.
    Int J Hematol. 2021 Sep 21. pii: 10.1007/s12185-021-03224.
    >> Share

  179. NAKAMAE H, Yamamoto M, Sakaida E, Kanda Y, et al
    Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year followup of the Japanese subgroup of the randomized ENESTnd trial.
    Int J Hematol. 2021 Sep 11. pii: 10.1007/s12185-021-03216.
    >> Share

  180. IZUMI A, Tachibana T, Ando T, Tanaka M, et al
    A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2021 Sep 6. pii: 10.1007/s12185-021-03217.
    >> Share

    August 2021
  181. HAN W, Zhou F, Wang Z, Hua H, et al
    Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Int J Hematol. 2021 Aug 27. pii: 10.1007/s12185-021-03210.
    >> Share

    July 2021
  182. KAKO S, Hayakawa F, Imai K, Tanaka J, et al
    Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
    Int J Hematol. 2021 Jul 30. pii: 10.1007/s12185-021-03198.
    >> Share

  183. SATOH T, Kayano H, Watanabe A, Ohta A, et al
    Lethal macrophage-related complications of juvenile myelomonocytic leukemia with a blastic crisis: an autopsy case report.
    Int J Hematol. 2021 Jul 16. pii: 10.1007/s12185-021-03189.
    >> Share

    June 2021
  184. LV K, Cai C, Chen J, Xu M, et al
    Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission.
    Int J Hematol. 2021 Jun 26. pii: 10.1007/s12185-021-03182.
    >> Share

  185. MORI T, Kikuchi T, Yamazaki R, Koda Y, et al
    Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2021;113:877-883.
    >> Share

    May 2021
  186. ARAKAWA Y, Masutani S, Oshima K, Mitani Y, et al
    Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia.
    Int J Hematol. 2021 May 18. pii: 10.1007/s12185-021-03163.
    >> Share

  187. MORITA K, Sasaki K
    Current status and novel strategy of CML.
    Int J Hematol. 2021;113:624-631.
    >> Share

  188. KIMURA S
    Evolution of CML treatment.
    Int J Hematol. 2021;113:622-623.
    >> Share

  189. SHAN M, Lu Y, Yang M, Wang P, et al
    Characteristics and transplant outcome of myeloid sarcoma: a single-institute study.
    Int J Hematol. 2021;113:682-692.
    >> Share

    April 2021
  190. KIDOGUCHI K, Ureshino H, Kizuka-Sano H, Yamaguchi K, et al
    Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Int J Hematol. 2021 Apr 27. pii: 10.1007/s12185-021-03156.
    >> Share

  191. CHUAH C, Koh LP, Numbenjapon T, Zang DY, et al
    Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
    Int J Hematol. 2021 Apr 13. pii: 10.1007/s12185-021-03144.
    >> Share

  192. KOBAYASHI T, Ubukawa K, Fujishima M, Takahashi N, et al
    Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
    Int J Hematol. 2021;113:600-605.
    >> Share

    February 2021
  193. ONO R, Ashiarai M, Hirabayashi S, Mizuki K, et al
    Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Int J Hematol. 2021;113:297-301.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016